subject:(glyburide)

University of Rhode Island

1. Bell, Samuel D. Understanding Pregnancy Centered Medications: Characterizing the Interactions of a Series of Sulfonylurea Analogs and the ATP Binding Cassette Transporter Proteins, P-Glycoprotein and Breast Cancer Resistance Protein.

Degree: 2017, University of Rhode Island

URL: https://digitalcommons.uri.edu/oa_diss/747

► The oral hypoglycemic agent Glyburide has been shown to be actively transported from various biological tissues though a pronounced interaction with the ATP binding cassette… (more)

▼ The oral hypoglycemic agent Glyburide has been shown to be actively transported from various biological tissues though a pronounced interaction with the ATP binding cassette (ABC) active transport proteins. Specifically, Glyburide is actively transported by the ABC proteins, P-glycoprotein (Pgp), Breast Cancer Resistance Protein (BCRP), and the Multidrug Resistance Proteins (MRP). This active transport occurs at various locations throughout the body but has been identified as being responsible for Glyburide’s unique placental transport behavior. Glyburide has been shown to not cross the placental barrier to any appreciable effect and will leave the placental barrier against the concentration gradient. Understanding this active transport creates the possibility of medicines designed specifically for pregnant women. The objective of this thesis is to investigate the activity of Glyburide and a series of sulfonylurea analogs against these two ABC transporter proteins. The transport of Glyburide and a series of sulfonylurea analogs in the presence of P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) was investigated in cell-based transport assays using two stably transfected Madin-Darby Canine Kidney cell lines, one overexpressing Pgp and the other overexpressing BCRP genes. The results of the transport studies confirm that both Pgp and BCRP play a role in the transport of the sulfonylureas. Further, in addition to Glyburide, the molecules Glimepiride, Glisoxepide, and Gliquidone were confirmed as Pgp and BCRP substrates, all of which has not previously been reported. Subsequently, the sulfonylurea transport activity with both Pgp and BCRP were used as the basis to build quantitative structure activity relationship (QSAR) and pharmacophore models. These models suggest that there are core molecular features necessary for the Pgp and BCRP activity, specifically that the arylsulfonylurea and benzamido ligands are required for both activities. We also found that increased hydrophobic character and increased bulky groups are key to both activities. The main differences in the activities were surrounding the sulfonylurea and amide moieties, with positive charge increasing the BCRP activity, and negative charge increasing the Pgp activity. Overall, the results of this research serve to provide improved knowledge for the design of pregnancy centered medications.

Subjects/Keywords: ABC; BCRP; Glyburide; Pgp; Transporters

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Bell, S. D. (2017). Understanding Pregnancy Centered Medications: Characterizing the Interactions of a Series of Sulfonylurea Analogs and the ATP Binding Cassette Transporter Proteins, P-Glycoprotein and Breast Cancer Resistance Protein. (Doctoral Dissertation). University of Rhode Island. Retrieved from https://digitalcommons.uri.edu/oa_diss/747

Chicago Manual of Style (16^th Edition):

Bell, Samuel D. “Understanding Pregnancy Centered Medications: Characterizing the Interactions of a Series of Sulfonylurea Analogs and the ATP Binding Cassette Transporter Proteins, P-Glycoprotein and Breast Cancer Resistance Protein.” 2017. Doctoral Dissertation, University of Rhode Island. Accessed April 15, 2021. https://digitalcommons.uri.edu/oa_diss/747.

MLA Handbook (7^th Edition):

Bell, Samuel D. “Understanding Pregnancy Centered Medications: Characterizing the Interactions of a Series of Sulfonylurea Analogs and the ATP Binding Cassette Transporter Proteins, P-Glycoprotein and Breast Cancer Resistance Protein.” 2017. Web. 15 Apr 2021.

Vancouver:

Bell SD. Understanding Pregnancy Centered Medications: Characterizing the Interactions of a Series of Sulfonylurea Analogs and the ATP Binding Cassette Transporter Proteins, P-Glycoprotein and Breast Cancer Resistance Protein. [Internet] [Doctoral dissertation]. University of Rhode Island; 2017. [cited 2021 Apr 15]. Available from: https://digitalcommons.uri.edu/oa_diss/747.

Council of Science Editors:

Bell SD. Understanding Pregnancy Centered Medications: Characterizing the Interactions of a Series of Sulfonylurea Analogs and the ATP Binding Cassette Transporter Proteins, P-Glycoprotein and Breast Cancer Resistance Protein. [Doctoral Dissertation]. University of Rhode Island; 2017. Available from: https://digitalcommons.uri.edu/oa_diss/747

Virginia Commonwealth University

2. Chojnacki, Jeremy E. NOVEL COMPOUNDS AS POTENTIAL ALZHEIMER'S DISEASE THERAPEUTICS AND INHIBITORS OF THE NLRP3 INFLAMMASOME.

Degree: PhD, Pharmaceutical Sciences, 2014, Virginia Commonwealth University

URL: https://doi.org/10.25772/62WY-9639 ; https://scholarscompass.vcu.edu/etd/3616

► Alzheimer’s disease is a devastating neurodegenerative disorder and the leading cause of dementia. The disease manifests via several pathologies including neuroinflammation, oxidative stress, metal… (more)

Subjects/Keywords: Alzheimer's Disease; NLRP3 Inflammasome; Curcumin; Melatonin; Diosgenin; Glyburide; Medicinal Chemistry and Pharmaceutics

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Chojnacki, J. E. (2014). NOVEL COMPOUNDS AS POTENTIAL ALZHEIMER'S DISEASE THERAPEUTICS AND INHIBITORS OF THE NLRP3 INFLAMMASOME. (Doctoral Dissertation). Virginia Commonwealth University. Retrieved from https://doi.org/10.25772/62WY-9639 ; https://scholarscompass.vcu.edu/etd/3616

Chicago Manual of Style (16^th Edition):

Chojnacki, Jeremy E. “NOVEL COMPOUNDS AS POTENTIAL ALZHEIMER'S DISEASE THERAPEUTICS AND INHIBITORS OF THE NLRP3 INFLAMMASOME.” 2014. Doctoral Dissertation, Virginia Commonwealth University. Accessed April 15, 2021. https://doi.org/10.25772/62WY-9639 ; https://scholarscompass.vcu.edu/etd/3616.

MLA Handbook (7^th Edition):

Chojnacki, Jeremy E. “NOVEL COMPOUNDS AS POTENTIAL ALZHEIMER'S DISEASE THERAPEUTICS AND INHIBITORS OF THE NLRP3 INFLAMMASOME.” 2014. Web. 15 Apr 2021.

Vancouver:

Chojnacki JE. NOVEL COMPOUNDS AS POTENTIAL ALZHEIMER'S DISEASE THERAPEUTICS AND INHIBITORS OF THE NLRP3 INFLAMMASOME. [Internet] [Doctoral dissertation]. Virginia Commonwealth University; 2014. [cited 2021 Apr 15]. Available from: https://doi.org/10.25772/62WY-9639 ; https://scholarscompass.vcu.edu/etd/3616.

Council of Science Editors:

Chojnacki JE. NOVEL COMPOUNDS AS POTENTIAL ALZHEIMER'S DISEASE THERAPEUTICS AND INHIBITORS OF THE NLRP3 INFLAMMASOME. [Doctoral Dissertation]. Virginia Commonwealth University; 2014. Available from: https://doi.org/10.25772/62WY-9639 ; https://scholarscompass.vcu.edu/etd/3616

University of Washington

3. Shuster, Diana Lyn. Of Mice and Women: Understanding Pregnancy-Induced Changes in Glyburide PK/PD for the Improved Management of Gestational Diabetes Mellitus (GDM).

Degree: PhD, 2014, University of Washington

URL: http://hdl.handle.net/1773/27226

► Pregnancy-induced changes in drug PK is explained by changes in physiology and expression of metabolic enzymes and transporters. We determined mRNA expression of enzymes and… (more)

▼ Pregnancy-induced changes in drug PK is explained by changes in physiology and expression of metabolic enzymes and transporters. We determined mRNA expression of enzymes and transporters in the maternal liver, kidney, small intestine, and placenta of pregnant mice by microarray analysis. A full summary of gene expression changes is listed in Supplemental Tables 1-14. Glyburide is commonly prescribed to treat gestational diabetes mellitus, a major complication of pregnancy. Gestational age-dependent changes in glyburide PK have not been characterized. We examined pregnancy-induced changes in the maternal-fetal disposition of glyburide and its primary metabolites using a pregnant mouse model, and found maternal CL, V<sub>&beta</sub>, and V_ss approximately doubled by mid-late gestation. Glyburide depletion rate in mouse liver microsomes increased as gestation progressed, suggesting increased CL is related to increased hepatic metabolism. Fetal exposure to glyburide was low, but doubled from mid to late pregnancy. Fetal exposure/metabolism of glyburide is also not well characterized. We determined the kinetic parameters of CYP3A enzymes for glyburide depletion; characterized glyburide metabolism by human fetal livers; and identified the enzyme responsible. M5 was the predominant metabolite generated by fetal CYP3A7 and human fetal liver microsomes (HFLMs). CYP3A7 protein levels in HFLMs were highly correlated with glyburide Clint, 16&alpha-OH DHEA formation, and 4′-OH MDZ formation. CYP3A5 and CYP3A7 genotype, fetal sex, gestational age, and post-mortem interval did not alter CYP3A7 protein expression or glyburide Clint. In recent years, oral hypoglycemic agents such as glyburide and metformin have gained increasing popularity for the treatment of GDM. Data is quite limited regarding the PD of glyburide and metformin during pregnancy. We completed an interim analysis of glyburide monotherapy, metformin monotherapy, or glyburide/metformin combination therapy in women with gestational diabetes compared to healthy pregnant women and non-pregnant women with type-2 diabetes mellitus receiving metformin. Pharmacodynamic analyses of blood glucose, insulin, and C-peptide data were performed, and estimates of insulin sensitivity, beta-cell responsivity, and disposition index (DI) were compared across treatment groups. The full study is still ongoing. Overall, this body of research provides novel insight for the optimization of oral hypoglycemic therapies in the management of gestational diabetes mellitus. Advisors/Committee Members: Mao, Qingcheng (advisor).

Subjects/Keywords: CYP3A; fetal; gestational diabetes; glyburide; pharmacokinetics; pregnancy; Pharmaceutical sciences; Obstetrics and gynecology; pharmaceutics

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Shuster, D. L. (2014). Of Mice and Women: Understanding Pregnancy-Induced Changes in Glyburide PK/PD for the Improved Management of Gestational Diabetes Mellitus (GDM). (Doctoral Dissertation). University of Washington. Retrieved from http://hdl.handle.net/1773/27226

Chicago Manual of Style (16^th Edition):

Shuster, Diana Lyn. “Of Mice and Women: Understanding Pregnancy-Induced Changes in Glyburide PK/PD for the Improved Management of Gestational Diabetes Mellitus (GDM).” 2014. Doctoral Dissertation, University of Washington. Accessed April 15, 2021. http://hdl.handle.net/1773/27226.

MLA Handbook (7^th Edition):

Shuster, Diana Lyn. “Of Mice and Women: Understanding Pregnancy-Induced Changes in Glyburide PK/PD for the Improved Management of Gestational Diabetes Mellitus (GDM).” 2014. Web. 15 Apr 2021.

Vancouver:

Shuster DL. Of Mice and Women: Understanding Pregnancy-Induced Changes in Glyburide PK/PD for the Improved Management of Gestational Diabetes Mellitus (GDM). [Internet] [Doctoral dissertation]. University of Washington; 2014. [cited 2021 Apr 15]. Available from: http://hdl.handle.net/1773/27226.

Council of Science Editors:

Shuster DL. Of Mice and Women: Understanding Pregnancy-Induced Changes in Glyburide PK/PD for the Improved Management of Gestational Diabetes Mellitus (GDM). [Doctoral Dissertation]. University of Washington; 2014. Available from: http://hdl.handle.net/1773/27226

University of Western Ontario

4. Clemens, Kristin K. Antihyperglycemic Medications and Hypoglycemia in Older Adults with Diabetes.

Degree: 2015, University of Western Ontario

URL: https://ir.lib.uwo.ca/etd/2914

► Background: In the last decade, several new antihyperglycemic medications have been approved to treat people with diabetes. However, the hypoglycemia risk of these medications in… (more)

Subjects/Keywords: diabetes; hypoglycemia; older adults; antihyperglycemic medications; glyburide; modified-release gliclazide; Endocrinology, Diabetes, and Metabolism

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Clemens, K. K. (2015). Antihyperglycemic Medications and Hypoglycemia in Older Adults with Diabetes. (Thesis). University of Western Ontario. Retrieved from https://ir.lib.uwo.ca/etd/2914

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Clemens, Kristin K. “Antihyperglycemic Medications and Hypoglycemia in Older Adults with Diabetes.” 2015. Thesis, University of Western Ontario. Accessed April 15, 2021. https://ir.lib.uwo.ca/etd/2914.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Clemens, Kristin K. “Antihyperglycemic Medications and Hypoglycemia in Older Adults with Diabetes.” 2015. Web. 15 Apr 2021.

Vancouver:

Clemens KK. Antihyperglycemic Medications and Hypoglycemia in Older Adults with Diabetes. [Internet] [Thesis]. University of Western Ontario; 2015. [cited 2021 Apr 15]. Available from: https://ir.lib.uwo.ca/etd/2914.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Clemens KK. Antihyperglycemic Medications and Hypoglycemia in Older Adults with Diabetes. [Thesis]. University of Western Ontario; 2015. Available from: https://ir.lib.uwo.ca/etd/2914

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

5. Pellerin, Marieve. Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie.

Degree: M. Sc., Sciences cliniques, 2015, Université de Sherbrooke

URL: http://www.collectionscanada.gc.ca/obj/thesescanada/vol2/QSHERU/TC-QSHERU-11143_8036.pdf ; http://savoirs.usherbrooke.ca/bitstream/11143/8036/8/Pellerin_Marieve_MSc_2015.pdf

► Résumé : Introduction : Le débat sur l’utilisation des hypoglycémiants oraux (HGO) dans le traitement du diabète gestationnel (DG) perdure. Plusieurs études ont montré que… (more)

▼ Résumé : Introduction : Le débat sur l’utilisation des hypoglycémiants oraux (HGO) dans le traitement du diabète gestationnel (DG) perdure. Plusieurs études ont montré que la metformine et le glyburide sont deux alternatives acceptables en grossesse. Malgré tout, l’insuline reste le choix de première intention pour le traitement du DG lorsque la diète et l’exercice physique ne suffisent plus. Les principaux arguments en faveur des HGO sont la possibilité d’une meilleure observance du traitement et une meilleure qualité de vie (QDV). Cependant, les études sur la QDV chez les femmes atteintes de DG sont rares et d’autres études sur le HGO sont nécessaires pour valider leur efficacité et innocuité dans le traitement du DG. Méthodes : Étude pilote; 73 patientes avec DG ont été randomisées au groupe HGO (metformine ± glyburide, et ajout d’insuline au besoin) ou au groupe insuline. L’objectif primaire est de comparer, entre les deux groupes, la préférence du traitement ainsi que plusieurs aspects de la QDV (état de santé général, bien-être général, satisfaction quant au traitement du diabète et dépression post-natale). Les objectifs secondaires étaient de comparer le contrôle glycémique maternel et les issues maternelles et néonatales. Résultats : Des 73 femmes recrutées, 68 ont été incluses pour analyses. Dans le groupe HGO (n=34), 35,3% des participantes ont reçu de l’insuline. Plus de femmes dans le groupe HGO ont mentionné préférer recevoir le même traitement pour une prochaine grossesse (72.7% vs. 42,4%, p=0.01) si un traitement s’avérait nécessaire. Aucune différence n’est ressortie pour l’état de santé général, le bien-être général, la satisfaction quant au traitement et la dépression post-natale. Le taux moyen d’hypoglycémies maternelles (glycémie < 3.3 mmol/L) était supérieur dans le groupe HGO (0.8 vs. 0.1, p=0.008). Il n’y a eu aucune différence dans les autres complications maternelles et néonatales. Conclusion : La QDV est similaire dans les deux groupes mais, si un traitement pharmacologique s’avérait nécessaire lors d’une prochaine grossesse, les femmes préfèreraient débuter par les HGO. L’utilisation des HGO n’était pas associée à une hausse cliniquement significative des complications maternelles et néonatales. Advisors/Committee Members: Ardilouze, Jean-Luc.

Subjects/Keywords: Diabète gestationnel; Hypoglycémiants oraux; Qualité de vie; Metfomine; Glyburide; Gestational diabetes; Oral hypoglycaemic agents; Quality of life; Metformin

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Pellerin, M. (2015). Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie. (Masters Thesis). Université de Sherbrooke. Retrieved from http://www.collectionscanada.gc.ca/obj/thesescanada/vol2/QSHERU/TC-QSHERU-11143_8036.pdf ; http://savoirs.usherbrooke.ca/bitstream/11143/8036/8/Pellerin_Marieve_MSc_2015.pdf

Chicago Manual of Style (16^th Edition):

Pellerin, Marieve. “Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie.” 2015. Masters Thesis, Université de Sherbrooke. Accessed April 15, 2021. http://www.collectionscanada.gc.ca/obj/thesescanada/vol2/QSHERU/TC-QSHERU-11143_8036.pdf ; http://savoirs.usherbrooke.ca/bitstream/11143/8036/8/Pellerin_Marieve_MSc_2015.pdf.

MLA Handbook (7^th Edition):

Pellerin, Marieve. “Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie.” 2015. Web. 15 Apr 2021.

Vancouver:

Pellerin M. Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie. [Internet] [Masters thesis]. Université de Sherbrooke; 2015. [cited 2021 Apr 15]. Available from: http://www.collectionscanada.gc.ca/obj/thesescanada/vol2/QSHERU/TC-QSHERU-11143_8036.pdf ; http://savoirs.usherbrooke.ca/bitstream/11143/8036/8/Pellerin_Marieve_MSc_2015.pdf.

Council of Science Editors:

Pellerin M. Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie. [Masters Thesis]. Université de Sherbrooke; 2015. Available from: http://www.collectionscanada.gc.ca/obj/thesescanada/vol2/QSHERU/TC-QSHERU-11143_8036.pdf ; http://savoirs.usherbrooke.ca/bitstream/11143/8036/8/Pellerin_Marieve_MSc_2015.pdf

Université de Sherbrooke

6. Pellerin, Marieve. Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie: Gestational diabetes : insulin or oral hypoglycemic agents? Pilot study on women treatment preference and its influence on quality of life.

Degree: 2015, Université de Sherbrooke

URL: http://hdl.handle.net/11143/8036

► Abstract: Background: The use of oral hypoglycemic agents (OHA) in gestational diabetes mellitus (GDM) is still debated. Insulin remains the first line treatment after diet… (more)

Subjects/Keywords: Diabète gestationnel; Hypoglycémiants oraux; Qualité de vie; Metfomine; Glyburide; Gestational diabetes; Oral hypoglycaemic agents; Quality of life; Metformin

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Pellerin, M. (2015). Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie: Gestational diabetes : insulin or oral hypoglycemic agents? Pilot study on women treatment preference and its influence on quality of life. (Masters Thesis). Université de Sherbrooke. Retrieved from http://hdl.handle.net/11143/8036

Chicago Manual of Style (16^th Edition):

Pellerin, Marieve. “Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie: Gestational diabetes : insulin or oral hypoglycemic agents? Pilot study on women treatment preference and its influence on quality of life.” 2015. Masters Thesis, Université de Sherbrooke. Accessed April 15, 2021. http://hdl.handle.net/11143/8036.

MLA Handbook (7^th Edition):

Pellerin, Marieve. “Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie: Gestational diabetes : insulin or oral hypoglycemic agents? Pilot study on women treatment preference and its influence on quality of life.” 2015. Web. 15 Apr 2021.

Vancouver:

Pellerin M. Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie: Gestational diabetes : insulin or oral hypoglycemic agents? Pilot study on women treatment preference and its influence on quality of life. [Internet] [Masters thesis]. Université de Sherbrooke; 2015. [cited 2021 Apr 15]. Available from: http://hdl.handle.net/11143/8036.

Council of Science Editors:

Pellerin M. Diabète gestationnel : insuline ou hypoglycémiants oraux ? Étude pilote de la préférence des femmes et de l'influence du traitement sur la qualité de vie: Gestational diabetes : insulin or oral hypoglycemic agents? Pilot study on women treatment preference and its influence on quality of life. [Masters Thesis]. Université de Sherbrooke; 2015. Available from: http://hdl.handle.net/11143/8036

University of Toronto

7. Pollex, Erika. Fetal Exposure to Antidiabetic Drugs: The Role of the Placenta.

Degree: 2010, University of Toronto

URL: http://hdl.handle.net/1807/24857

►

Gestational diabetes, a common medical complication in pregnancy, may lead to severe fetal consequences if left untreated. A major concern with the use of antidiabetic… (more)

▼

Gestational diabetes, a common medical complication in pregnancy, may lead to severe fetal consequences if left untreated. A major concern with the use of antidiabetic drugs in pregnancy is the potential for placental transfer and fetal toxicity. The presence of endocytic pathways and several ABC transporter proteins has been demonstrated in the human placenta and are believed to play an important role in determining fetal exposure to drugs used in pregnancy. The objective of this thesis is to investigate the safety and transfer of the oral hypoglycemic agent, glyburide, and the new long acting insulin analog, insulin glargine, across the human placenta. The oral antidiabetic, glyburide, has been shown to be actively effluxed across the placenta in the fetal to maternal direction. The transport of glyburide in the presence of a breast cancer resistance protein (BCRP) inhibitor was investigated in the dually perfused human placenta model. The results of the perfusion studies indicate that BCRP plays a role in protecting the fetus from the accumulation of glyburide. Subsequently, cellular studies were carried out to determine the effect of the naturally occurring single nucleotide polymorphism within the coding region of BCRP (C421A/Q141K) on glyburide transport. Results suggest that glyburide transport may be reduced in the presence of the Q141K polymorphism. While insulin remains as the gold standard, the potential for maternal hypoglycemia with insulin injection has resulted in the development of insulin analogs. Insulin glargine, a human insulin analog, has a long half life with no pronounced peak when compared to currently used NPH insulin. Human placental perfusion experiments examining the extent and rate of transfer of insulin glargine across the placenta demonstrated that, at therapeutic concentrations, insulin glargine does not cross the placenta to a measurable extent. To further determine the fetal safety of insulin glargine therapy compared with NPH insulin, a systematic review and meta-analysis were performed. No evidence was identified for increased adverse fetal outcomes with the use of insulin glargine during pregnancy. Overall, the results of this research serve to provide improved treatment options for women with diabetes in pregnancy.

PhD

Advisors/Committee Members: Koren, Gideon, Pharmaceutical Sciences.

Subjects/Keywords: gestational diabetes; placental transport; insulin glargine; glyburide; 0419; 0383

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Pollex, E. (2010). Fetal Exposure to Antidiabetic Drugs: The Role of the Placenta. (Doctoral Dissertation). University of Toronto. Retrieved from http://hdl.handle.net/1807/24857

Chicago Manual of Style (16^th Edition):

Pollex, Erika. “Fetal Exposure to Antidiabetic Drugs: The Role of the Placenta.” 2010. Doctoral Dissertation, University of Toronto. Accessed April 15, 2021. http://hdl.handle.net/1807/24857.

MLA Handbook (7^th Edition):

Pollex, Erika. “Fetal Exposure to Antidiabetic Drugs: The Role of the Placenta.” 2010. Web. 15 Apr 2021.

Vancouver:

Pollex E. Fetal Exposure to Antidiabetic Drugs: The Role of the Placenta. [Internet] [Doctoral dissertation]. University of Toronto; 2010. [cited 2021 Apr 15]. Available from: http://hdl.handle.net/1807/24857.

Council of Science Editors:

Pollex E. Fetal Exposure to Antidiabetic Drugs: The Role of the Placenta. [Doctoral Dissertation]. University of Toronto; 2010. Available from: http://hdl.handle.net/1807/24857

Université de Sherbrooke

8. Tessier, Daniel. Le glyburide comparé au gliclazide dans le diabète non insulino-dépendant du sujet âgé.

Degree: 1993, Université de Sherbrooke

URL: http://hdl.handle.net/11143/13012

► L'objectif de cette étude est de comparer l'effet de deux sullfonylurées de deuxième génération soit le glyburide et le gliciazide, sur la fréquence des phénomènes… (more)

▼ L'objectif de cette étude est de comparer l'effet de deux sullfonylurées de deuxième génération soit le glyburide et le gliciazide, sur la fréquence des phénomènes hypoglycémiques et sur le contrôle du diabète dans une population de sujets âgés atteints de diabète de type 2 (aussi appelé diabète non Insulinodépendant). Vingt-deux sujets âgés non traités ont été randomisés à double Insu entre le glyburide et le gliciazide. Avant de débuter le traitement, les épreuves suivantes ont été réalisées chez chaque participant : un bilan biochimique, une hyperglycémie provoquée orale sur 3 heures et un clamp hyperglycémique de deux heures (le glucose a été augmenté de 5.4 mmol/l au-dessus du niveau basal). Les patients ont été évalués régulièrement sur une période de 6 mois pour évaluer le contrôle de leur diabète ainsi que la survenue d'hypoglycémies symptomatiques. L'hyperglycémie provoquée orale et le clamp hyperglycémique ont été répétés 1 et 6 mois après un contrôle glycémique jugé optimal avec la médication. L'aire sous la courbe pour les valeurs glycémiques obtenues durant l'hyperglycémie provoquée orale (glyburide : 15.5 ± 2.3 mmol/l, gliclazide : 14.9 ± 2.4 mmol/l) ainsi que les valeurs d'hémoglobine glycosylée ( glyburide: 7.4 ± 0.7 %, gliciazide : 7.9 ± 1.6 %) tendaient à montrer un contrôle du diabète comparable entre les deux groupes à 6 mois. Le nombre d'événements hypoglycémiques était statistiquement plus élevé dans le groupe traité avec glyburide que le groupe traité avec gliciazide ( 17 vs 4 , p<0.01). L'Indice de sensibilité à l'Insuline ( ml/kg/min./pmol x 100) a été augmenté de façon significative par le glyburide (0.284 + 0.116 (ligne de base) versus 0.518 ± 0.102 (6 mois) , p<0.05) mais non par le gliclazide (0.260 ± 0.048 (ligne de base) versus 0.358 ± 0.0.048 (6 mois), p=ns). Nous en concluons que les deux médicaments que nous avons évalué semblent procurer un contrôle glycémique équivalent dans les deux groupes. La survenue d'hypoglycémies est plus importante avec le glyburide que le gliclazide possiblement parce que ce médicament augmente la sensibilité à l’insuline de façon significative comparativement au gliclazide. Advisors/Committee Members: Tétrault, Jean-Pierre (advisor).

Subjects/Keywords: Diabète non insulino-dépendant; Glyburide; Gliclazide; Âgé

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Tessier, D. (1993). Le glyburide comparé au gliclazide dans le diabète non insulino-dépendant du sujet âgé. (Masters Thesis). Université de Sherbrooke. Retrieved from http://hdl.handle.net/11143/13012

Chicago Manual of Style (16^th Edition):

Tessier, Daniel. “Le glyburide comparé au gliclazide dans le diabète non insulino-dépendant du sujet âgé.” 1993. Masters Thesis, Université de Sherbrooke. Accessed April 15, 2021. http://hdl.handle.net/11143/13012.

MLA Handbook (7^th Edition):

Tessier, Daniel. “Le glyburide comparé au gliclazide dans le diabète non insulino-dépendant du sujet âgé.” 1993. Web. 15 Apr 2021.

Vancouver:

Tessier D. Le glyburide comparé au gliclazide dans le diabète non insulino-dépendant du sujet âgé. [Internet] [Masters thesis]. Université de Sherbrooke; 1993. [cited 2021 Apr 15]. Available from: http://hdl.handle.net/11143/13012.

Council of Science Editors:

Tessier D. Le glyburide comparé au gliclazide dans le diabète non insulino-dépendant du sujet âgé. [Masters Thesis]. Université de Sherbrooke; 1993. Available from: http://hdl.handle.net/11143/13012

9. Mistri,Hirenkumar Natvarlal. LC ESI MS MS methods for quantification of drugs in human biological matrices and their application to bioequivalence study;.

Degree: Chemistry, 2015, Gujarat University

URL: http://shodhganga.inflibnet.ac.in/handle/10603/45406

Abstract Not Available

Data not available

Advisors/Committee Members: Shrivastav,Pranav S.

Subjects/Keywords: Alfuzosin; Drugs-Metformin; Glyburide; N-Desmethyl; Solifenacin; Sulfamethoxazole; Trimethoprim; Zopiclone-N-Oxide

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Natvarlal, M. (2015). LC ESI MS MS methods for quantification of drugs in human biological matrices and their application to bioequivalence study;. (Thesis). Gujarat University. Retrieved from http://shodhganga.inflibnet.ac.in/handle/10603/45406

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Natvarlal, Mistri,Hirenkumar. “LC ESI MS MS methods for quantification of drugs in human biological matrices and their application to bioequivalence study;.” 2015. Thesis, Gujarat University. Accessed April 15, 2021. http://shodhganga.inflibnet.ac.in/handle/10603/45406.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Natvarlal, Mistri,Hirenkumar. “LC ESI MS MS methods for quantification of drugs in human biological matrices and their application to bioequivalence study;.” 2015. Web. 15 Apr 2021.

Vancouver:

Natvarlal M. LC ESI MS MS methods for quantification of drugs in human biological matrices and their application to bioequivalence study;. [Internet] [Thesis]. Gujarat University; 2015. [cited 2021 Apr 15]. Available from: http://shodhganga.inflibnet.ac.in/handle/10603/45406.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Natvarlal M. LC ESI MS MS methods for quantification of drugs in human biological matrices and their application to bioequivalence study;. [Thesis]. Gujarat University; 2015. Available from: http://shodhganga.inflibnet.ac.in/handle/10603/45406

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Washington

10. Dorfman, Elizabeth Howard. Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure.

Degree: PhD, 2015, University of Washington

URL: http://hdl.handle.net/1773/34161

► This dissertation is principally comprised of three distinct but related projects. The first is an assessment of the quantity and nature of obstetric pharmacology clinical… (more)

Subjects/Keywords: ABCG2; breast cancer resistance protein; fetal drug exposure; glyburide; obstetric pharmacology; placental drug transport; Genetics; Pharmacology; Obstetrics and gynecology; public health genetics

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Dorfman, E. H. (2015). Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure. (Doctoral Dissertation). University of Washington. Retrieved from http://hdl.handle.net/1773/34161

Chicago Manual of Style (16^th Edition):

Dorfman, Elizabeth Howard. “Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure.” 2015. Doctoral Dissertation, University of Washington. Accessed April 15, 2021. http://hdl.handle.net/1773/34161.

MLA Handbook (7^th Edition):

Dorfman, Elizabeth Howard. “Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure.” 2015. Web. 15 Apr 2021.

Vancouver:

Dorfman EH. Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure. [Internet] [Doctoral dissertation]. University of Washington; 2015. [cited 2021 Apr 15]. Available from: http://hdl.handle.net/1773/34161.

Council of Science Editors:

Dorfman EH. Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure. [Doctoral Dissertation]. University of Washington; 2015. Available from: http://hdl.handle.net/1773/34161

11. Gainey, Stephen Joseph. Hypoxic immunomodulation results in increased disease risk and altered behavior via non-canonical pathways.

Degree: PhD, Animal Sciences, 2017, University of Illinois – Urbana-Champaign

URL: http://hdl.handle.net/2142/97658

► Hypoxia is a potent immunomodulatory condition that underlies a wide array of disease states and associated comorbidities. Inflammation appears to be a critical factor in… (more)

▼ Hypoxia is a potent immunomodulatory condition that underlies a wide array of disease states and associated comorbidities. Inflammation appears to be a critical factor in the adverse psychological outcomes linked with hypoxia/reoxygenation injury. A causative role for brain-based IL-1 has been suggested in hypoxia-induced cognitive impairment and anxiety-like behaviors. However, the exact mechanism responsible has yet to be fully understood. Therefore, in this study we examined the impact of acute hypoxia on hippocampal-independent memory recall and particular cellular localization of inflammasome activity within the amygdala. Mice were exposed to hypoxic (6% oxygen/94% nitrogen) or normoxic (ambient) conditions for a period of 2 hours. Following 2 hours of reoxygenation, mice showed 65% increased caspase-1 activity in the amygdala by ICV-IHC determination with no significant changes observed within the hippocampus. To determine the extent of inflammasome activation in hypoxia/reoxygenation injury, drugs targeting potential activators such as K+ efflux and A2A adenosine receptor were administered. After glyburide (K+ efflux antagonist) and 3,7-dimethyl-1-prop-2-ynyl-purine-2,6-dione (DMPX-A2A adenosine receptor antagonist) administration, both drugs significantly reduced the level of caspase-1 activation in the amygdala correlating with the restoration of performance on the novel object recognition memory (NOR) task and thus mitigating hypoxia-induced retrograde amnesia. To determine the cellular localization of caspase-1 activation within the amygdala, a dual stain protocol was developed and showed that hypoxia induced significantly greater co-localization of caspase-1 and neurons. This result demonstrates the contribution of neuronal cells to the increased activation of caspase-1 following hypoxia/reoxygenation. Interestingly, IGF-I neuron-specific knockout mice showed similarly reduced caspase-1 activation in the amygdala and correction of NOR performance. In addition, hypoxia/reoxygenation significantly increased serine phosphorylation of insulin-receptor substrate 1 (IRS-1) and p70 S6 Kinase (p70SK) in whole brain. However, no change in IGF-I, protein kinase A (PKA), or cyclic AMP (cAMP) was observed in either the amygdala or hippocampus. These results suggest that hypoxia-induced retrograde amnesia is dependent on caspase-1 activation in the amygdala via a neuronal K+ efflux, A2A adenosine receptor, and IGF-I associated mechanism. Next, we examined a real-life scenario in which hypoxic conditions have been observed such as that displayed in obesity or following chronic high-fat diet (HFD) intake. In this study, mice were fed a HFD from weaning for 1, 3 or 6 weeks. Similar to hypoxia, mice displayed impaired NOR performance after 1 and 3 weeks of HFD consumption when compared to low-fat diet (LFD) controls but surprisingly recovered performance after 6 weeks of diet. In a hippocampal-dependent task, object location recognition (OLR), HFD consumption did not impair cognition until 3 and 6 weeks of diet.… Advisors/Committee Members: Freund, Gregory G (advisor), Freund, Gregory G (Committee Chair), Beever, Jonathan E (committee member), Salak-Johnson, Janeen L (committee member), Horn, Gavin P (committee member).

Subjects/Keywords: Hypoxia; High-fat; Neuroinflammation; Caspase-1; Memory impairment; Novel object; Cognition; Anxiety; Glyburide; Adenosine

…COGNITIVE IMPAIRMENT ARE IMPROVED WITH TREATMENT BY GLYBURIDE… …observed in the hippocampus. Mice were then injected with glyburide and DMPX to understand the… …involvement of K+ efflux/A2A AR. Both glyburide and DMPX significantly reduced the level of caspase… …was administered ICV at a dose of 100 ng/µl/mouse 30 minutes post-hypoxia. Glyburide (… …90% reduction in hypoxia-induced caspase-1 activation in the amygdala after glyburide…

10 more images…

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Gainey, S. J. (2017). Hypoxic immunomodulation results in increased disease risk and altered behavior via non-canonical pathways. (Doctoral Dissertation). University of Illinois – Urbana-Champaign. Retrieved from http://hdl.handle.net/2142/97658

Chicago Manual of Style (16^th Edition):

Gainey, Stephen Joseph. “Hypoxic immunomodulation results in increased disease risk and altered behavior via non-canonical pathways.” 2017. Doctoral Dissertation, University of Illinois – Urbana-Champaign. Accessed April 15, 2021. http://hdl.handle.net/2142/97658.

MLA Handbook (7^th Edition):

Gainey, Stephen Joseph. “Hypoxic immunomodulation results in increased disease risk and altered behavior via non-canonical pathways.” 2017. Web. 15 Apr 2021.

Vancouver:

Gainey SJ. Hypoxic immunomodulation results in increased disease risk and altered behavior via non-canonical pathways. [Internet] [Doctoral dissertation]. University of Illinois – Urbana-Champaign; 2017. [cited 2021 Apr 15]. Available from: http://hdl.handle.net/2142/97658.

Council of Science Editors:

Gainey SJ. Hypoxic immunomodulation results in increased disease risk and altered behavior via non-canonical pathways. [Doctoral Dissertation]. University of Illinois – Urbana-Champaign; 2017. Available from: http://hdl.handle.net/2142/97658

		in
And / Or
		in
And / Or
		in
And / Or
		in

Open Access Theses and Dissertations